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Summary. The mechanisms of tumor growth and progression involve the activation of 
different processes such as neovascularization and angiogenesis. These processes 
involve tumoral cells and stromal cells. Hence, inhibiting angiogenesis affects tumor 
growth and proliferation in patients with different types of cancer. 
Nevertheless, tumoral cells and stromal components are responsible for the resistance to 
antiangiogenic therapies. The majority of tumors respond to this type of therapy; 
however, some tumors may be indifferent to antiangiogenic therapies (intrinsic 
resistance) and other tumors become resistant during treatment (acquired resistance). 
Different strategies have been proposed to prevent resistance. Preclinical studies and 
clinical trials are focused to fight this therapeutic approach in order to prevent or delay 










Angiogenesis in tumor development 
The main characteristics of cancer cells is the lack of controlling cellular divisionand 
are able to grow as neoplastic lesion composed of tumor cells and stroma. Both types of 
cells structurally and functionally contribute to tumor development. Nevertheless, the 
neoplastic lesion cannot form a tumor mass beyond a certain limiting size, generally 1–
2 mm³, due to a lack of proper diffusion of oxygen and other essential nutrients. Then, 
tumors induce blood vessel growth, angiogenesis, by up-regulating the expression and 
secretion of various pro-angiogenic growth factors such as vascular endothelial growth 
factor (VEGF), fibroblast growth factors (FGFs), angiopoietins (Ang), placental growth 
factor (PlGF), and some integrins, and concomitantly down-regulating several anti-
angiogenic factors [1]. Furthermore, there are evidences that the angiogenic process 
precedes the formation of the tumor, suggesting that angiogenesis may represent the 
rate-limiting step not only for tumor growth, but also to the occurrence of malignant 
tumors [2]. In addition, angiogenesis coincides with increased circulating tumor cells 
facilitating metastatic spread. 
Thus, tumor cells cooperate with other cell types of the tumor microenvironment 
to achieve the essential feature of angiogenesis. Immune cells, inflammatory cells, 
hematopoietic cells and stromal fibroblasts contribute to activate endothelial cells of 
tumor angiogenesis by secretion of various types of inducers [3]. Interestingly, tumors 
often show an inflammatory phenotype, described by Dvorak in 1986 as “wounds that 
never heal,” which could tip the balance in favor of angiogenesis and thus promote the 
formation of new vasculature able to oxygenate and nourish the growing tumor mass.  
The imbalance in producing sustained pro-angiogenic factors, together with the 
persistent lack of vasculature stabilizing factors, leads to the formation of immature and 
dysfunctional vascular system that cannot keep pace with the rapid growth of the tumor 
mass. Therefore, the vascular tree in a tumor is typically chaotic with dead-end vascular 
branches and areas of inverted and intermittent blow flow, which some impairs the 
vascular function and leads to regions of lowered perfusion and hypoxia. Nevertheless, 
different types of tumors have low oxygenates areas (hypoxic regions) and present up-
regulation of different transcriptions factors such as HIFs and hypoxia-depend genes 
(Carbonic anhydrase, glucose transporters...) [4]. 
Different processes such as glycolytic metabolism, oxygen consumption, survival, 
angiogenesis, migration and invasion could be modulated through HIF-1, nevertheless 
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their stabilization has an important repercussion in the behavior of the cells and in their 
gene expression profile [5, 6].     
Moreover, hypoxia actively participates in the activation of tumor angiogenesis, this 
being responsible for regulating the inducers and inhibitors factors that contribute to 
angiogenesis. It is in fact capable of regulating the expression of molecules that disrupt 
endothelium and pericyte coverage, as angiopoietin-2, which further contributesto the 
start of sprouting (developing vascular branches). Furthermore, multiple types of 
mobilizing stem cells from the bone marrow and the recruitment of immune cells to the 
tumor microenvironment are positively modulated by tumor hypoxia [7]. 
Interestingly, recent advances in molecular biology techniques and the study of 
families with hereditary renal cancer (Syndromes ‘Von Hippel-Lindau,’ ‘Hereditary 
papillary,’ ‘Birt-Hogg-Dube’ and ‘hereditary leiomyomatosis and renal cancer’) have 
permitted the recognition of genes and proteins involved in the pathogenesis of some 
tumor entities, giving the ability to select the most appropriate therapy for a given 
disease[8, 9]. In particular, inactivation of the VHL gene (tumor suppressor gene) in 
patients with RCC involves hyper activation of HIF1α signaling due to lack of 
degradation even under normoxia, resulting in an accumulation of HIF which promotes 
transcription its down-stream effectors such as VEGF, GLUT1, TGF-α and PDGF [10, 
11]. Therefore, the therapy against VEGF and the usage of inhibiting molecules of the 
receptor that binds ligand have been used in many types of tumors [12, 13] 
 
Anti-angiogenic strategies 
The neoplastic dependence on tumor angiogenesis and the stromal contribution to the 
formation of new vessels suggested new therapeutic targets to control tumor growth. 
Recent approaches in cancer therapy are targeting endothelial cells that help tumor 
growth. These cells are genetically more stable and accumulate less mutations; allowing 
them to prevent drug resistance. Since in 1971 Judah Folkman proposed the inhibition 
of angiogenesis as a target for cancer treatment, several anti-angiogenic drugs have been 
developed mainly targeting endothelial cells. More recently, other cell types in the 
tumor microenvironment different or together with endothelial cells have been propose 
as therapeutic target, such as pericytes, which contribute to the maturation of the 
vasculature sending signals of survival to endothelial cells and structurally supporting 





Fig. 1. Angiogenesis as a therapeutic target. The use of angiogenesis as a therapeutic 
target is the basis of current clinical treatments in several type of tumors. Initially FDA 
approved the use of blocking VEGF antibody (bevacizumab) in combination with 
chemotherapy in metastatic colorectal cancer, metastatic breast cancer and other 
cancers. Later on, chemical inhibitors of VEGF receptor 2 (VEGFR2) as sunitinib or 
sorafenib have been approved in the first line used as monotherapy for metastatic 
kidney cancer. In addition, new recombinant molecules such as VEGF TRAP, receptor-
blocking antibodies have been developed, and other pro-angiogenic factors (i.e. FGF) or 
endogenous anti-angiogenic molecules (i.e. SEMAs) have been proposed as possible 
future anti-angiogenic targets for therapy. 
 
Based on their mechanism of action we classify anti-angiogenic drugs in two 
groups: 
Direct Anti-angiogenic drugs. those that prevent vascular endothelial cells from 
proliferating, migrating or avoiding cell death in response to a spectrum of pro-
angiogenic proteins, including VEGF, FGF, IL-8, platelet-derived growth factor 




Indirect Anti-angiogenic drugs. those that secondarily prevent the expression or block 
the activity of tumor proteins that activate angiogenesis. Their target is a signaling 
pathway in the tumor cells responsible for synthesis or secretion of pro-angiogenic 
molecules. The typical example being mTOR inhibitors that target a tumor cell survival 
pathway and secondarily decrease VEGF expression thus secondarily indirectly exert an 
anti-angiogenic effect. 
 
In this review we will only cover the direct anti-angiogenic drugs, which are 
typically directed to inhibit pro-angiogenic signaling pathways. For its role as the main 
promoter of angiogenesis, vascular endothelial growth factor (VEGF) is the main target 
of the anti-angiogenic drugs currently approved [1]. 
 
VEGF as a prototypical angiogenesis target 
Monoclonal Antibodies: they have a direct and indirect action. The direct action is to 
block the ligand (VEGF) or its receptors (VEGFRs), which blocks its signaling 
function. The indirect action is mediated by the immune system (complement system 
activation, cytotoxic lymphocytes and macrophages) and contributes to the destruction 
of the tumor cell. This class is the first anti-angiogenic drug that demonstrated a clear 
clinical effect increasing survival in metastatic colorectal cancer. The most well-known 
example is Bevacizumab, an antibody against human VEGF ligand [15]. 
 
Selective inhibitors of kinase activity: compete with ATP for binding to the catalytic 
domain of the protein, thereby blocking the kinase activity of VEGFRs. These drugs 
also were initially tested as anti-proliferative agents for tumor endothelial cells, which 
started the development of a large number of inhibitors that act at different pathways 
and cell types apart from VEGFRs (promiscuous tyrosine-kinase inhibition profile). 
Currently sunitinib and sorafenib are the most widely used drugs of this class since they 
demonstrate the best anti-angiogenic activity [16]. 
 
Other novel targets recently proposed 
FGF-FGFR inhibitors: the fibroblast growth factor/fibroblast growth factor receptor 
(FGF/FGFR) signaling axis plays an important role in normal organ, vascular, and 
skeletal development. Deregulation of FGFR signaling through genetic modification or 
overexpression of the receptors (or their ligands) has been observed in numerous tumor 
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as the FGF/FGFR axis also plays a key role in driving tumor angiogenesis. Pre-
clinical data shows that inhibition of FGFR signaling can result in anti-proliferative 
and/or pro-apoptotic effects, both in vitro and in vivo, thus confirming the validity of the 
FGF/FGFR axis as a potential therapeutic target [17]. Several drugs agains different 
pro-angiogenic targets have been developed for their anti-angiogenic effect in pre-
clinical and clinical studies [1] 
 
Sema-like ligand: semaphorins (SEMAs) are a superfamily of secreted or membrane- 
associated glycoproteins implicated in the control of axonal wiring and involved 
in angiogenesis and cancer progression. The proliferation, cell survival, alteration in cell 
adhesion and tumor invasiveness can be positively or negatively modulated in tumoral 
cells by SEMAs [18]. These can also alter cell migration and proliferation in stromal 
components [19, 20]. Thus, increased expression in Sema3E produced a decrease in 
tumor burden, neutralizing tumor angiogenesis and moreover increasing the metastatic 
capacity of tumors. 
Casazza et al deeply explored the pleiotropic therapeutic activities associated to an 
uncleavable Sema3E isoform (Uncl-Sema3E) [18, 21]. SEMAs have antiangiogenic 
activity and also anti-invasiveness and anti-metastatic effect on the tumor [18] 
Endogenous p61-Sema3E isoform binds to PlxnD1 in endothelial cells inducing SEMA-
driven antiangiogenic collapsing response. 
Furthermore, in tumor cells, the Uncl-Sema3E-PlxnD1complex fails to elicit the ErbB2-
mediated pro-invasive and pro-metastatic pathway [18] 
With these results they proposed Uncl-Sema3E as a novel anti-angiogenic and anti-
metastatic therapeutic approach. 
Angiopoietin2 inhibition: the angiopoietins are proteingrowth factors that promote 
angiogenesis and help stabilize the development of blood vessels from pre-existing 
blood vessels. Ang1 and Ang2 are required for the formation of mature blood vessels, 
as demonstrated by mouse knock out studies [22]. Moreover, Ang2 is critically 
associated tumor angiogenesis and progression. It has been described that Ang2 
regulates tumor angiogenesis in cooperation with VEGF as well as Ang1 through the 
Tie2-dependent pathways. On the other hand, Ang2 stimulates tumor angiogenesis, 
invasion, and metastasis through Tie2-independent pathways involving integrin-
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mediated signaling.Therefore, Ang2 is currently an attractive therapeutic target, as it has 
been corroborated by recent studies using a neutralizing anti-Ang2 antibody [23]. 
 
CLINICAL CONTROVERSIAL RESULTS  
Pre-clinical studies often report positive results about the benefit of anti-angiogenic 
treatment, but clinical trials’ results vary depending on the cancer type and anti-
angiogenic therapy used. Phase III studies have indeed shown the benefits of 
Bevacizumab or Sunitinib as well as other VEGF-targeted therapies, either as single 
agents or in combination with chemotherapy. Blocking the formation of new blood 
vessels with anti-angiogenic therapy is currently used to treat certain types of cancers, 
including metastatic renal cancer [12, 13]. Therefore, the metastatic renal cell carcinoma 
which is characterized by being dependent on VEGF growth is controlled by the 
antiangiogenic therapy, confirming the positive effect of this kind of therapy and 
supported by various clinical trials [24-27]. Nevertheless, many authors coincide in the 
observation that anti-angiogenic treatments are more effective in the increase of 
theprogression free survival (PFS) than on the prolongation of overall survival (OS). 
However, based on obvious clinical benefits with a remarkable increase in PFS although 
in the absence of robust statistically significant increase in OS, VEGF pathway 
inhibitors are the mainstay of therapy in RCC approved by FDA [28-30]. This 
discrepancy between PFS and OS feeds the controversy of how to best measure clinical 
benefit of treatment, because anti-angiogenic therapies typically exert an effect in terms 
of increased necrosis as observed by imaging studies. As mentioned before, 
antiangiogenic treatments have an effect on cavitation and loss of viable tumor burden, 
causing an impact in tumor growth with no alteration in the parameters of RECIST 
(Response Evaluation Criteria in Solid Tumors) [31, 32]. 
Tumor development is deeply affected by tumor type and induces modifications 
on the formation of tumors; in particular by their own angiogenic characteristics and 
their pro-angiogenic capacity coming from tumor-stroma specific interaction. 
The inactivation of VHL tumor suppressor is highly frequent in RCC [33], for 
that reason angiogenesis is presumably highly dependent on VEGF. Similar to 
hepatocellular carcinoma (HCC) that are particularly angiogenic when growing in liver 
displacing the normal parenchyma, moreover the dependence on angiogenesis is 
presumed to be the key for the efficacy of antiangiogenic therapy. On the contrary, 
colon-rectal cancer (CRC) shows considerably less clinical benefits and VEGF-targeted 
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therapy is therefore administered in combination with chemotherapy. On the other hand 
metastatic foci of CRC, typically growing in the liver, often replaces the liver 
parenchyma, rather than displacing it, by the FAS ligand-induced death in the 
hepatocytes. This leads to the co-option of existing blood vessels instead of dependence 
on sprouting angiogenesis [30, 31, 34]. 
The adaptability of the tumors to classical chemo-therapy and radiation emerges 
also for anti-angiogenic therapy [35, 36]. Thus, anti-angiogenic therapies have proven to 
be beneficial in many patients, but these clinical benefits are overshadowed by apparent 
acquired resistance to anti-angiogenic therapies. Moreover, some patients don´t respond 
to these therapies at all demonstrating upfront refractoriness to therapy or intrinsic 
resistance.  
 
Resistance to antiangiogenic therapy 
The initial assumption was that antiangiogenic therapy does not cause resistance, 
because it was specific against endothelial cells that showed no genetic instability [37]. 
However, experimental and clinical evidence has shown that the benefit of this therapy 
have been mild and transitory [13]. 
The majority of tumors respond to therapy but it is important to differentiate between 
refractoriness, intrinsic or acquired resistance [31]. 
Intrinsic resistance (IR) to anti-angiogenic therapy. In this type of resistance the 
tumor becomes indifferent to antiangiogenic therapy and there is no response to 
treatment (Figure 2). Some patients treated with  Bevacizumab, Sorafenib, and Sunitinib 
developed this type of resistance [38, 39]. 
It has been shown that tumors are capable of expressing from the beginning of 
its progression multiple pro-angiogenic factors, so that anti-VEGF therapy is not fully 
effective, as it is only able to partially block the process of angiogenesis [40]. Another 
molecular mechanism that may be involved in the intrinsic resistance is the de-
regulation of the HIF pathway. In the tumors with activation of HIF, such as renal 
tumors, are consistently found high levels of genes of pro-angiogenic molecules 
controlled by this factor, thereby reducing the effect of anti-angiogenic therapy [12, 13]. 
Other mechanisms could be independence from angiogenesis process that have a role in 
tumor revascularization, including sprouting, co-option of pre-existing vessels, 





Fig. 2. Modes of resistance to anti-angiogenic therapy. Two types of resistance to anti-
angiogenic therapies have been described: Intrinsic Resistance or refractoriness defined 
as total lack of response to antiangiogenic therapy. The specific mechanisms of 
resistance of this type include the multiplicity of pro-angiogenic factors produced by 
tumor or stromal cells within tumor mass or vascular co-option. The therapy is unable to 
reduce or stabilize tumors and there is no beneficial effect of anti-angiogenic therapy. 
Acquired Resistance refers to adaptive capacity presented by tumors leading to evade 
the therapeutic blockage after a phase of effectiveness. Induced adaptive mechanisms, 
including overexpression of pro-angiogenic factors, recruitment of vascular progenitor 
cells (BMDCs) and increase pericytes coverage. Altogether, they allow for 
revascularization despite therapeutic inhibition, allowing for tumor regrowth and the 
progression of the disease. 
 
Could the differential angiogenic features of each tumor have a repercussion in 
their upfront sensitivity or resistance to anti-angiogenic therapy? Interestingly in 
astrocytomas, a class of highly oxygen dependent brain tumors, their development is 
mediated by changes in the way of tumors acquires their supply through blood vessels. . 
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Thus low-grade astrocytomas grow coopting pre-existing normal brain vessels whereas 
progressing from grade III to grade IV, so called glioblastoma multiforme  (GBM), an 
enhanced request of oxygen and nutrients activates an angiogenic program [42]. 
Bevacizumab was approved by the United States Food and Drug Administration 
(FDA) for the treatment of recurrent GBM based on several studies demonstrating 
efficacy in terms of increased PFS and OS in combination with conventional 
chemotherapy [30]. 
Unfortunately, tumor resistance occurs with new distant foci of progression or 
diffuse in-situ infiltration associated or not with local tumor recurrence as shown by 
fluid attenuated inversion recovery (FLAIR) and magnetic resonance imaging (MRI) 
analysis [30, 43, 44]. 
 
Acquired resistance (AR) to anti-angiogenic therapy. In addition to the traditional 
resistance of some drugs, which is acquired by mutations that affect the target of drugs 
or alterations of entry mechanisms of the compound [45] the AR resistance to anti-
angiogenic therapies is more indirect and evasive. Typically, alternative mechanisms are 
created that lead to activation of angiogenesis even when the target of the drug remains 
inhibited [46]. Tumors have long been shown to have remarkable plasticity and 
adaptability to classical chemotherapy and radiation, which contributes to resistance to 
anti-angiogenic therapy [3, 47, 48]. However, the specific mechanisms of acquired 
resistance to anti-angiogenic therapies are unique, and many of these mechanisms show 
reversibility after anti-angiogenic therapy has been stopped (Paez-Ribes and Casanovas, 
unpublished observations). Indicating that these types of resistance could 
reflect the adaptations to therapy instead of mutations or gene 
amplifications characterizing acquired resistance to other therapeutic strategies. In fact, 
clinical evidence of this reversibility has been described in metastatic renal cell 
carcinoma treated repeatedly with VEGFR inhibitors [13, 18]. 
Several different mechanisms of acquired resistance to anti-angiogenic therapy have 
been described among which are (Fig. 2): 
 Overexpression of alternative pro-angiogenic factors: initially be described in 
pre-clinical a transgenic mouse model of neuroendocrine tumors (RIP-Tag2). 
After receiving anti-VEGFR2 therapy there is a reduction of angiogenesis 
followed by initial tumor regrowth reinduction induced angiogenesis. This 
reinduction is promoted by overexpression of pro-angiogenic factors VEGF-
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independent, as fibroblast growth factor 1 (FGF1), FGF2, ephrin A1 (EFNA1), 
EFNA2, and angiopoietin1 (ANGPT1). [36, 49]. 
 Recruitment of stromal pro-angiogenic cells: hypoxic conditions induced by 
anti-angiogenic treatment promote the recruitment of large numbers of cells 
derived from bone marrow (BMDCs) at the boundaries of the tumor. These cells 
have the ability to promote tumor revascularization [50] 
 Vessel coverage by pericytes: preexisting tumor vessels that have a high number 
of pericytes surface coverage remain functional and exhibit no regression [2, 51-
53]. This suggests that endothelial cells have the ability to recruit pericytes, 
which are able to secrete VEGF and other factors promoting their survival [2, 
54, 55]. 
  Vascular mimicry: defined as the formation of microvascular channels by the 
aggressive tumor cells themselves, which would allow the transport of oxygen 
and nutrients [41]. 
 
Interestingly, there are some parallelism among the mechanisms that lead to IR and AR. 
The difference lies in the intrinsic characteristics of each tumor as tumors with AR 
require some time in order to generate these molecular changes and become resistant to 
this therapy, whereas tumors with IR are immune to this therapy since from the 
beginning have over expression of these factors. Furthermore, resistance to anti-
angiogenic therapies for cancer implicates tumor cells and stromal components, but its 
contribution is relatively different in each cancer subtype.  
One crucial step for the development of the neoplastic lesion is the interaction between 
tumor cells and tumor microenvironments; moreover the tumor-stromal cell 
collaboration is also involved in tumor responses to therapeutic inhibition of VEGF-
pathway [30]. 
However, tumor and stroma cells contribute to the inefficacy of the therapy in tumors 
that present intrinsic resistance similar to acquired resistance tumors 
Most of the tumors present different mechanisms of resistance that depend on cells  
which involve the modification of the stroma components across the modification of the 
stroma as the recruitment of infiltrating cells, such as cancer-associated fibroblasts 
(CAFs) and tumor-associated macrophages (TAMs), or the production of alternative 
pro-angiogenic factors [30]. One of the main modifications induced by anti-angiogenic 
treatment in tumors is the increase of hypoxia and HIF-1 stabilization. Interestingly, 
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neoplastic cells could react to hypoxia becoming tolerant and modifying the metabolic 
characteristics to resist to low levels of oxygen. Alternatively, tumor cells could engage 




Hence, approaching antiangiogenic resistance is a key step in the generation of novel 
antiangiogenic drugs. A number of strategies have been postulated to prevent resistance, 
targeting multi-pathway inhibitors or multi-combination of anti-angiogenic therapies 
that inhibit different pathways that could avoid resistance. Moreover, the plasticity to 
the treatments observed in pre-clinical studies suggest a new therapeutic hypothesis that 
sequential treatment with an anti-angiogenic drug followed by a non-anti-angiogenic 
drug (i.e. another targeted therapy or chemotherapy) could resensitize patients to 
another anti-angiogenic drug as a third line of treatment. Obviously, many studies are 
warranted to unravel the pre-clinical basis and clinical potential of these strategies to 
finally determine its clinical benefit for patients. 
 
Furthermore, the implication of stroma in the emergence of resistance to anti-angiogenic 
therapies definitively has important clinical implications. First of all it reveals another 
relevant culprit causing the short-lasting effects of anti-angiogenic in neoplastic 
patients, thus alleviating the exclusive fault of tumor cells. Secondarily, it opens 
innovative perspectives for the prevention of resistance and pro-invasive effects of anti-
angiogenic therapy, such as the modulation of the emerging pro-metastatic stroma. 
Therefore, as both tumor cells, stroma and their interactions initiate tumorigenesis, 
sustain neoplastic growth, and allow for metastatization and therapeutic resistance, these 
two neoplastic partners should be considered in the development of new therapeutic 
approaches. In this sense, clinical studies that investigate and address these approaches 
in the coming years are warranted. 
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